Nu-Med Plus, Inc.

NUMDdata completeness 63%14 fiscal years on file

Data notes: no data for concept 'totalDebt'

i. The business — what you’d actually own

Figure	FY 2021	FY 2022	FY 2023	FY 2024	FY 2025
Revenue	—	—	—	—	—
Net income	−$830,061¹	−$130,167²	−$125,526³	−$68,345⁴	−$56,182⁴
Operating cash flow	−$206,831⁵	−$38,480⁶	−$66,389⁷	−$4,433⁸	−$47,979⁸
Capital expenditure	—	—	—	—	—
Free cash flow (derived)	—	—	—	—	—
Total debt	—	—	—	—	—
Cash & equivalents	$11,675⁹	$73,195¹⁰	$6,806¹¹	$2,373¹¹	$661¹²
Diluted shares	73.4M	80.0M	81.7M	83.5M	83.5M

Superscripts are receipts. Each links to the SEC filing the number came from (full list at the bottom).

ii. Your slice — ownership made literal

If you owned

Net assets behind them

−$0.03

your share of equity

Profit it earned you last year

−$0.01

Free cash flow it threw off

—

Debt you’d be carrying

—

10 shares is a claim on −$0.03 of net worth that earned you −$0.01 last year.

iii. Is this a good business?

Moat signal · return on equity

— avg · 5y

Not enough data in the filings for a return-on-capital reading.

Management signal · capital allocation

+14% shares · 5y

Share count is up 14% over 5 years — owners have been diluted. Worth asking what they got for it.

Signals, not verdicts — read from the filings above. Numbers don’t prove a moat; they show its footprint. You decide.

iv. What it’s worth — engine v0.1.0

DCF · Growth Exit 10Y

not applicable

only 0 years of FCF (need ≥3) — model not applicable

DCF · Growth Exit 5Y

not applicable

only 0 years of FCF (need ≥3) — model not applicable

Earnings Power Value

not applicable

normalized (5y-median) earnings non-positive — EPV undefined

Graham Number

not applicable

diluted EPS missing or non-positive — Graham Number undefined

Different models answer different questions — which to trust when →

Sources — the receipts